Gene therapy for Parkinson’s disease: A decade of progress supported by posthumous contributions from volunteer subjects

Neural Regeneration Research

Volumn 10, Issue 10, 2015, Pages 1586-1588

  Bartus, Raymond T ^a  

^a RTBioconsultants Inc ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE; NEURTURIN; TYROSINE 3 MONOOXYGENASE; VIRUS VECTOR;

AUTOPSY; DEATH; DEGENERATIVE DISEASE; DISEASE DURATION; GENE THERAPY; HUMAN; IMMUNOCYTOCHEMISTRY; NEUROPATHOLOGY; NONHUMAN; NOTE; PARKINSON DISEASE; PHASE 2 CLINICAL TRIAL (TOPIC); POSITRON EMISSION TOMOGRAPHY; POSTHUMOUS CARE; PROTEIN EXPRESSION; PUTAMEN; RANDOMIZED CONTROLLED TRIAL (TOPIC); SHY DRAGER SYNDROME; SUBSTANTIA NIGRA; TOPOGRAPHY; UNIFIED PARKINSON DISEASE RATING SCALE;

EID: 84945585558     PISSN: 16735374     EISSN: 18767958     Source Type: Journal    
DOI: 10.4103/1673-5374.167783     Document Type: Note

References (9)

1. Bankiewicz KS, Forsayeth J, Eberling JL, Sanchez-Pernaute R, Pivirotto P, Bringas J, Herscovitch P, Carson RE, Eckelman W, Reutter B, Cunningham J (2006) Long-term clinical improvement in MPTP-lesioned primates after gene therapy with AAV-hAADC. Mol Ther 14:564-570.
2. Bartus RT, Weinbert MS, Samulski RJ (2014) Parkinson’s disease gene therapy: Success by design meets failure by efficacy. Mol Ther 22:487-497.
3. Bartus RT, Baumann TL, Brown L, Kruegel BR, Ostrove JM, Herzog CD (2013) Advancing neurotrophic factors as treatments for age-related neurodegenerative diseases: developing and demonstrating “clinical proof-of-concept” for AAV-neurturin (CERE-120) in Parkinson’s disease. Neurobiol Aging 34:35-61.
4. Bartus RT, Herzog CD, Chu Y, Wilson A, Brown L, Johnson E, Olanow CW, Mufson EJ, Kordower JH (2011) Bioactivity of AAV2-NeurturinNRTN gene therapy (CERE-120) in Parkinson’s disease: A comparison of post-mortem and nonhuman primate brain tissue. Mov Disord 26:27-36.
5. Bartus RT, Kordower JH, Johnson EM Jr, Brown L, Kruegel BR, Chu Y, Baumann TL, Lang AE, Olanow CW, Herzog CD (2015) Post-mortem assessment of the short and long-term effects of the trophic factor neurturin in patients with α-synucleinopathies. Neurobiol Dis 78:162-171.
6. Kordower JH, Olanow CW, Dodiya HB, Chu Y, Beach TG, Adler CH, Halliday GM, Bartus RT (2013) Disease duration and the integrity of the nigrostriatal system in Parkinson’s disease. Brain 136:2419-2431.
7. Marks WJ Jr, Bartus RT, Siffert J, Davis CS, Lozano A, Boulis N, Vitek J, Stacy M, Turner D, Verhagen L, Bakay R, Watts R, Guthrie B, Jankovic J, Simpson R, Tagliati M, Alterman R, Stern M, Baltuch G, Starr PA, et al. (2010) Gene delivery of AAV2-neurturin for Parkinson’s disease: a double-blind, randomised, controlled trial. Lancet Neurol 9:1164-1172.
8. Mittermeyer G, Christine CW, Rosenbluth KH, Baker SL, Starr P, Larson P, Kaplan PL, Forsayeth J, Aminoff MJ, Bankiewicz KS (2012) Long-term evaluation of a phase 1 study of AADC gene therapy for Parkinson’s disease. Hum Gene Ther 23:377-381.
9. Warren Olanow C, Bartus RT, Baumann TL, Factor S, Boulis N, Stacy M, Turner DA, Marks W, Larson P, Starr PA, Jankovic J, Simpson R, Watts R, Guthrie B, Poston K, Henderson JM, Stern M, Baltuch G, Goetz CG, Herzog C, et al. (2015) Gene delivery of neurturin to putamen and substania nigra in Parkinson disease: A double-blind, randomized controlled trial. Ann Neurol 78:248-257.